Baillie Gifford & CO Nu Cana PLC Transaction History

Baillie Gifford & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 06, 2021	BUY	$4.38 - $7.0 $1.49 Million - $2.38 Million	339,700 Added 10.23%	3,659,030 $18.3 Million
Q4 2020 Feb 10, 2021	BUY	$4.4 - $5.59 $1.19 Million - $1.51 Million	269,800 Added 8.85%	3,319,330 $14.9 Million
Q3 2020 Nov 12, 2020	BUY	$4.57 - $6.48 $10.2 Million - $14.4 Million	2,222,222 Added 268.61%	3,049,530 $15.8 Million
Q3 2018 Nov 13, 2018	BUY	$20.12 - $26.86 $3.46 Million - $4.62 Million	171,858 Added 26.22%	827,308 $20.6 Million
Q2 2018 Jul 17, 2018	BUY	$19.0 - $29.84 $272,270 - $427,607	14,330 Added 2.24%	655,450 $12.5 Million
Q1 2018 May 10, 2018	BUY	$10.04 - $28.25 $914,844 - $2.57 Million	91,120 Added 16.57%	641,120 $12.1 Million
Q4 2017 Feb 13, 2018	BUY	$10.0 - $18.72 $1 Million - $1.87 Million	100,000 Added 22.22%	550,000 $5.56 Million
Q3 2017 Oct 20, 2017	BUY	$16.15 - $18.37 $7.27 Million - $8.27 Million	450,000	450,000 $8.27 Million

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $64.2M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.